Alzchem Group AG Reports Record Year in 2025 with Robust Sales and EBITDA

Alzchem Group AG, renowned for its focus on specialty chemicals, announced a record year in 2025. Group sales soared to €562.1 million, while EBITDA rose to €116.5 million, exceeding forecasts. An increased dividend of €2.10 per share is planned.

The company's growth defied industry challenges as subdued demand and cost pressures affected many. Strong demand in niche markets, particularly creatine products, bolstered results, with the Specialty Chemicals segment driving earnings growth. Meanwhile, the Basics & Intermediates segment faced a decline due to weak steel industry demands.

Despite increased investments, free cash flow stayed positive at €40.1 million. Future plans include capacity expansions in Germany and a new US site, anticipating further growth in 2026 with sales projected at €600 million and EBITDA at €126 million.